Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of BI 10773 with placebo control and sitagliptin comparator in type 2 diabetes
2010-022718-17Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of empagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: No primary endpoints defined. Started Nov 2010; status: completed.
02
Drugs
empagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-022718-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022718-17.